Last updated: April 25, 2026
Who supplies Neupro (rotigotine) and what is the downstream supply chain?
Neupro is a rotigotine transdermal patch (brand: Neupro; active ingredient: rotigotine). The drug is marketed in multiple markets through local marketing authorization holders (MAHs) and distributed by local wholesalers or contracted logistics partners. Because “suppliers” can mean different roles (MAH, manufacturer of drug product, manufacturer of active pharmaceutical ingredient, or logistics distributors), the only defensible way to answer is to map the roles from official regulatory product labels and market authorizations.
What Neupro’s supplier landscape looks like by role (global pattern)
| Role in supply chain |
Typical entity type |
What “proof” sources usually show |
| Marketing Authorization Holder (MAH) |
Company holding the authorization in a territory |
Product label, EU/US registration dossier references, national regulator pages |
| Drug product manufacturer (patch assembly and packaging) |
Contract manufacturer and/or internal manufacturing unit |
Label manufacturing site statements; dossier/manufacturer listings in regulator files |
| API supplier (rotigotine) |
API manufacturer (internal or contract) |
Dossier API manufacturer listings; sometimes disclosed on label or in registration documents |
| Distributor / logistics supplier (wholesalers) |
National distribution network |
Wholesale channel listings; not usually consistent across countries |
Key constraints that affect any “supplier list” for Neupro
- Neupro is regulated and supplied territory-by-territory. The MAH and local distributor can change by country even when the underlying drug product manufacturing sites remain constant.
- Public labels often disclose only the MAH and sometimes the drug product manufacturer, not the API supplier.
What companies are involved with Neupro supply in the public record?
The public record for Neupro consistently points to:
- Neupro’s originator brand owner in Europe: UCB (Neupro is a UCB-branded product).
- Multiple manufacturing locations for the transdermal patch and packaging, typically listed on country labels and/or European product information.
To produce an accurate, complete “supplier list,” you need an explicit country (or a single authoritative registry that enumerates MAH and manufacturing sites for all territories). Without that, you risk mixing roles and territories.
Practical supplier map for decision-making
Use this approach when building a supplier shortlist for sourcing, due diligence, or competitive intelligence.
1) MAH (Marketing Authorization Holder)
Identify the MAH for the target market. This determines:
- who controls regulatory communications for that jurisdiction
- who typically governs supply contracts for local distribution
2) Drug product manufacturer
Identify the manufacturer(s) listed on the package for:
- patch manufacturing
- packaging (secondary packaging and distribution readiness)
This is the supplier that matters for:
- manufacturing capacity and batch release risk
- supply continuity and change control
3) API supplier
Identify rotigotine API manufacturer(s) from the dossier/regulator files. This matters for:
- raw material availability and lead times
- upstream constraints during API shortages
Key takeaways
- Neupro supply is territory-specific. MAH and distributors can differ by country, even when the active and patch format stay the same.
- The only supplier mapping that holds up under regulatory diligence is role-based: MAH, drug product manufacturer, and API supplier.
- For a complete and accurate “supplier list,” you must tie to a specific jurisdiction/product label/dossier.
FAQs
-
Is Neupro manufactured by UCB or outsourced?
Neupro’s drug product manufacturing is commonly performed via specific manufacturing sites that may include contract manufacturing. The definitive answer depends on the country label/manufacturer listing.
-
Who holds the marketing authorization for Neupro?
The MAH is jurisdiction-dependent; Neupro is an UCB brand, but local MAH can vary by territory.
-
Do the API and patch manufacturing sites have to be the same company?
No. API supply is typically upstream from drug product manufacturing and can involve separate manufacturers.
-
How do I confirm the drug product manufacturer for my target market?
Use the package labeling and the corresponding regulator product information for that country.
-
Does Neupro have multiple distributors?
Yes. Distribution through wholesalers/logistics partners is territory-dependent.
Sources
[1] UCB. Neupro (rotigotine) product information (brand and regulatory background). https://www.ucb.com/
[2] European Medicines Agency (EMA). Neupro (rotigotine) EPAR and product information references. https://www.ema.europa.eu/
[3] US FDA. Drug product and labeling records for rotigotine transdermal system (Neupro) where applicable. https://www.fda.gov/
